GlobeNewsWire
09 Jun 2026, 12:45 UTC · 15w ago
Verdict
Headline takes no side. We score PALI +0.40 across three claims — moderately bullish.
+0.40moderately bullish
More positive than 63% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Palisade Bio is advancing its lead program, PALI-2108, toward Phase 2 clinical studies in ulcerative colitis (UC) and Crohn’s disease.
More positive than 77% of claims this week
PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials for UC and fibrostenotic Crohn’s disease (FSCD).
So whatPositive early-phase data reduces technical risk and provides a foundation for the upcoming Phase 2 trials.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
Palisade Bio's CMO will present preclinical findings and the scientific rationale for PALI-2108 at the New York Academy of Sciences symposium.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 63% of ticker scores this week
The company is presenting promising research on its lead drug candidate at a prestigious scientific symposium.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
6h ago
−7.5%
Price is moving against the score
$1.61 vs $1.74 close before publication (Jun 8) · not market-adjusted
PALI chart →
